178 related articles for article (PubMed ID: 35618478)
1. Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose
Feng Y; Meshaw R; Zhao XG; Jannetti S; Vaidyanathan G; Zalutsky MR
J Nucl Med; 2023 Jan; 64(1):124-130. PubMed ID: 35618478
[TBL] [Abstract][Full Text] [Related]
2. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
[TBL] [Abstract][Full Text] [Related]
3. Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.
Feng Y; Zhou Z; McDougald D; Meshaw RL; Vaidyanathan G; Zalutsky MR
Nucl Med Biol; 2021 Jan; 92():171-183. PubMed ID: 32448731
[TBL] [Abstract][Full Text] [Related]
4. Labeling single domain antibody fragments with
Zhou Z; McDougald D; Meshaw R; Balyasnikova I; Zalutsky MR; Vaidyanathan G
Nucl Med Biol; 2021; 100-101():24-35. PubMed ID: 34146837
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an
Feng Y; Meshaw R; McDougald D; Zhou Z; Zhao XG; Jannetti SA; Reiman RE; Pippen E; Marjoram R; Schaal JL; Vaidyanathan G; Zalutsky MR
Sci Rep; 2022 Feb; 12(1):3020. PubMed ID: 35194100
[TBL] [Abstract][Full Text] [Related]
6. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
[TBL] [Abstract][Full Text] [Related]
7. Labeling a TCO-functionalized single domain antibody fragment with
Zhou Z; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2020 Sep; 28(17):115634. PubMed ID: 32773089
[TBL] [Abstract][Full Text] [Related]
8. Site-Specific and Residualizing Linker for
Zhou Z; Meshaw R; Zalutsky MR; Vaidyanathan G
J Nucl Med; 2021 Nov; 62(11):1624-1630. PubMed ID: 33637584
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
Vaidyanathan G; McDougald D; Choi J; Koumarianou E; Weitzel D; Osada T; Lyerly HK; Zalutsky MR
J Nucl Med; 2016 Jun; 57(6):967-73. PubMed ID: 26912425
[TBL] [Abstract][Full Text] [Related]
10. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
[TBL] [Abstract][Full Text] [Related]
11. Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent.
Feng Y; Sarrett SM; Meshaw RL; Vaidyanathan G; Cornejo MA; Zeglis BM; Zalutsky MR
J Med Chem; 2022 Nov; 65(22):15358-15373. PubMed ID: 36368007
[TBL] [Abstract][Full Text] [Related]
12. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
[TBL] [Abstract][Full Text] [Related]
13. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
[TBL] [Abstract][Full Text] [Related]
14. Low-level whole-brain radiation enhances theranostic potential of single-domain antibody fragments for human epidermal growth factor receptor type 2 (HER2)-positive brain metastases.
Procissi D; Jannetti SA; Zannikou M; Zhou Z; McDougald D; Kanojia D; Zhang H; Burdett K; Vaidyanathan G; Zalutsky MR; Balyasnikova IV
Neurooncol Adv; 2022; 4(1):vdac135. PubMed ID: 36128586
[TBL] [Abstract][Full Text] [Related]
15. N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization.
Choi J; Vaidyanathan G; Koumarianou E; McDougald D; Pruszynski M; Osada T; Lahoutte T; Lyerly HK; Zalutsky MR
Nucl Med Biol; 2014; 41(10):802-12. PubMed ID: 25156548
[TBL] [Abstract][Full Text] [Related]
16. d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution.
Pruszynski M; Kang CM; Koumarianou E; Vaidyanathan G; Zalutsky MR
Molecules; 2018 May; 23(5):. PubMed ID: 29783774
[TBL] [Abstract][Full Text] [Related]
17. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics.
Huynh TT; Feng Y; Meshaw R; Zhao XG; Rosenfeld L; Vaidyanathan G; Papo N; Zalutsky MR
Nucl Med Biol; 2024 Apr; 134-135():108913. PubMed ID: 38703588
[TBL] [Abstract][Full Text] [Related]
18. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
20. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
[Next] [New Search]
